Cargando…

A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients

OBJECTIVES: Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez-Gallego, Esther, Gómez, Josep, Pacheco, Yolanda M., Peraire, Joaquim, Viladés, Consuelo, Beltrán-Debón, Raúl, Mallol, Roger, López-Dupla, Miguel, Veloso, Sergi, Alba, Verónica, Blanco, Julià, Cañellas, Nicolau, Rull, Anna, Leal, Manuel, Correig, Xavier, Domingo, Pere, Vidal, Francesc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844590/
https://www.ncbi.nlm.nih.gov/pubmed/29280761
http://dx.doi.org/10.1097/QAD.0000000000001730
_version_ 1783305261590511616
author Rodríguez-Gallego, Esther
Gómez, Josep
Pacheco, Yolanda M.
Peraire, Joaquim
Viladés, Consuelo
Beltrán-Debón, Raúl
Mallol, Roger
López-Dupla, Miguel
Veloso, Sergi
Alba, Verónica
Blanco, Julià
Cañellas, Nicolau
Rull, Anna
Leal, Manuel
Correig, Xavier
Domingo, Pere
Vidal, Francesc
author_facet Rodríguez-Gallego, Esther
Gómez, Josep
Pacheco, Yolanda M.
Peraire, Joaquim
Viladés, Consuelo
Beltrán-Debón, Raúl
Mallol, Roger
López-Dupla, Miguel
Veloso, Sergi
Alba, Verónica
Blanco, Julià
Cañellas, Nicolau
Rull, Anna
Leal, Manuel
Correig, Xavier
Domingo, Pere
Vidal, Francesc
author_sort Rodríguez-Gallego, Esther
collection PubMed
description OBJECTIVES: Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor immunological recovery after antiretroviral therapy (ART) to envisage the underlying mechanistic pathways that influence the treatment response. DESIGN: This was a multicentre, prospective cohort study in ART-naive and a pre-ART low nadir (<200 cells/μl) HIV-infected patients (n = 64). METHODS: We obtained clinical data and metabolomic profiles for each individual, in which low molecular weight metabolites, lipids and lipoproteins (including particle concentrations and sizes) were measured by NMR spectroscopy. Immunological recovery was defined as reaching CD4(+) T-cell count at least 250 cells/μl after 36 months of virologically successful ART. We used univariate comparisons, Random Forest test and receiver-operating characteristic curves to identify and evaluate the predictive factors of immunological recovery after treatment. RESULTS: HIV-infected patients with a baseline metabolic pattern characterized by high levels of large high density lipoprotein (HDL) particles, HDL cholesterol and larger sizes of low density lipoprotein particles had a better immunological recovery after treatment. Conversely, patients with high ratios of non-HDL lipoprotein particles did not experience this full recovery. Medium very-low-density lipoprotein particles and glucose increased the classification power of the multivariate model despite not showing any significant differences between the two groups. CONCLUSION: In HIV-infected patients, a baseline healthier metabolomic profile is related to a better response to ART where the lipoprotein profile, mainly large HDL particles, may play a key role.
format Online
Article
Text
id pubmed-5844590
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-58445902018-03-20 A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients Rodríguez-Gallego, Esther Gómez, Josep Pacheco, Yolanda M. Peraire, Joaquim Viladés, Consuelo Beltrán-Debón, Raúl Mallol, Roger López-Dupla, Miguel Veloso, Sergi Alba, Verónica Blanco, Julià Cañellas, Nicolau Rull, Anna Leal, Manuel Correig, Xavier Domingo, Pere Vidal, Francesc AIDS Basic Science OBJECTIVES: Poor immunological recovery in treated HIV-infected patients is associated with greater morbidity and mortality. To date, predictive biomarkers of this incomplete immune reconstitution have not been established. We aimed to identify a baseline metabolomic signature associated with a poor immunological recovery after antiretroviral therapy (ART) to envisage the underlying mechanistic pathways that influence the treatment response. DESIGN: This was a multicentre, prospective cohort study in ART-naive and a pre-ART low nadir (<200 cells/μl) HIV-infected patients (n = 64). METHODS: We obtained clinical data and metabolomic profiles for each individual, in which low molecular weight metabolites, lipids and lipoproteins (including particle concentrations and sizes) were measured by NMR spectroscopy. Immunological recovery was defined as reaching CD4(+) T-cell count at least 250 cells/μl after 36 months of virologically successful ART. We used univariate comparisons, Random Forest test and receiver-operating characteristic curves to identify and evaluate the predictive factors of immunological recovery after treatment. RESULTS: HIV-infected patients with a baseline metabolic pattern characterized by high levels of large high density lipoprotein (HDL) particles, HDL cholesterol and larger sizes of low density lipoprotein particles had a better immunological recovery after treatment. Conversely, patients with high ratios of non-HDL lipoprotein particles did not experience this full recovery. Medium very-low-density lipoprotein particles and glucose increased the classification power of the multivariate model despite not showing any significant differences between the two groups. CONCLUSION: In HIV-infected patients, a baseline healthier metabolomic profile is related to a better response to ART where the lipoprotein profile, mainly large HDL particles, may play a key role. Lippincott Williams & Wilkins 2018-03-13 2018-03-07 /pmc/articles/PMC5844590/ /pubmed/29280761 http://dx.doi.org/10.1097/QAD.0000000000001730 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Basic Science
Rodríguez-Gallego, Esther
Gómez, Josep
Pacheco, Yolanda M.
Peraire, Joaquim
Viladés, Consuelo
Beltrán-Debón, Raúl
Mallol, Roger
López-Dupla, Miguel
Veloso, Sergi
Alba, Verónica
Blanco, Julià
Cañellas, Nicolau
Rull, Anna
Leal, Manuel
Correig, Xavier
Domingo, Pere
Vidal, Francesc
A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients
title A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients
title_full A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients
title_fullStr A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients
title_full_unstemmed A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients
title_short A baseline metabolomic signature is associated with immunological CD4(+) T-cell recovery after 36 months of antiretroviral therapy in HIV-infected patients
title_sort baseline metabolomic signature is associated with immunological cd4(+) t-cell recovery after 36 months of antiretroviral therapy in hiv-infected patients
topic Basic Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844590/
https://www.ncbi.nlm.nih.gov/pubmed/29280761
http://dx.doi.org/10.1097/QAD.0000000000001730
work_keys_str_mv AT rodriguezgallegoesther abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT gomezjosep abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT pachecoyolandam abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT perairejoaquim abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT viladesconsuelo abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT beltrandebonraul abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT mallolroger abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT lopezduplamiguel abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT velososergi abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT albaveronica abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT blancojulia abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT canellasnicolau abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT rullanna abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT lealmanuel abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT correigxavier abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT domingopere abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT vidalfrancesc abaselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT rodriguezgallegoesther baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT gomezjosep baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT pachecoyolandam baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT perairejoaquim baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT viladesconsuelo baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT beltrandebonraul baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT mallolroger baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT lopezduplamiguel baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT velososergi baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT albaveronica baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT blancojulia baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT canellasnicolau baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT rullanna baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT lealmanuel baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT correigxavier baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT domingopere baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients
AT vidalfrancesc baselinemetabolomicsignatureisassociatedwithimmunologicalcd4tcellrecoveryafter36monthsofantiretroviraltherapyinhivinfectedpatients